Tecan Group Ag · SIX:TECN
Tecan — Technical Presentation (2023)
28 slides from Tecan's technical presentation, Apr 24, 2023
Slide 1: Scaling the potential of patient-derived organoids through automation and label-free image analysis
Scaling the potential of patient-derived organoids through automation and label-free image analysis of individual organoids Christophe Deben UAntwerp Tumoroid Screening lab (TUSC) Orbits
Slide 2: Dawn of the organoid era
Dawn of the organoid era o 3D ‘micro-tumors’ generated directly from patient samples o Maintain mutational landscape and clonal heterogeneity o Translational application: predict therapy response o Preclinical application: accelerated drug development o Biobanking Tuveson et al., Science, 2021 2
Slide 3: Drug screening current limitation
Drug screening current limitation Treat organoids ? Incubate for 3-7 days Cell Lysis Growth arrest? Measure ATP Cell death? Homo/heterogeneous response? Influence metabolic changes? Relative viability 3
Slide 4: Drug screening: live cell imaging
Drug screening live cell imaging 4 Tecan Spark® Cyto is for research use only. Not for use in diagnostic procedures.
Slide 5: Drug screening: live cell imaging
Drug screening live cell imaging 5
Slide 6: Drug screening: growth rate-based drug response metrics
Drug screening growth rate-based drug response metrics 6
Slide 7: Cytostatic, NDR, Cytotoxic
Drug screening growth rate-based drug response metrics 1 Cytostatic 052 NDR 0 060 087 Cytotoxic -1 1 32 1024 32768 Concentration Gemcitabine (nM) Gupta, A., et al. 2020 Deben, C., et al. 2022 7 Le Compte, M., et al. 2022
Slide 8: Relative viability vs normalised drug response
Drug screening growth rate-based drug response metrics Relative viability Normalised drug response 8
Slide 9: Sensitive, mixed response, resistant
Sensitive Mixed response Invading cells? Resistant 9
Slide 10: Single organoid drug response: Affected Fraction
Drug screening single organoid drug response Affected Fraction 10
Slide 11: Single organoid drug response: Invasive Fraction
Drug screening single organoid drug response Invasive Fraction 11
Slide 12: Single organoid drug response
Drug screening single organoid drug response High fraction affected High invasive fraction Large size Low fraction affected 12
Slide 13: Single organoid drug response
Drug screening single organoid drug response High fraction affected High invasive fraction Large size Low fraction affected 13
Slide 14: Orbits prediction score
Drug screening Orbits prediction score Prediction Score 14 Created with BioRender.com
Slide 15: Drug screening workflow
Drug screening workflow 15 Created with BioRender.com
Slide 16: Drug screening synergy
Drug screening synergy Auranofin (TrxRi, drug repurposing) Created with BioRender.com 16 Tecan D300e Digital Dispenser is for research use only. Not for use in diagnostic procedures. Tecan D300e Digital Dispenser is a product of HP Inc. CA, USA.
Slide 17: Drug screening synergy
Drug screening synergy https://synergyfinder.fimm.fi/ 17
Slide 18: Drug screening synergy
Drug screening synergy 18 Created with BioRender.com
Slide 19: Drug screening synergy
Drug screening synergy 19 Created with BioRender.com
Slide 20: Drug screening synergy
Drug screening synergy 20 Created with BioRender.com
Slide 21: Drug screening synergy
Drug screening synergy 21 Created with BioRender.com
Slide 22: Drug screening synergy: Buparlisib, MK2206, Everolimus
Drug screening synergy Buparlisib MK2206 Everolimus 22 Created with BioRender.com
Slide 23: pocococees
ry pocococees ° aT iE lin - S 2 green mask ® Mojs a ~Oecdiia
Slide 24: User Storage
= User Storage ie 0.21/10.00 GB | Image Viewer +6 ) <n Name Size (GB) Experiments Last Modified (Europe/Brussels) Progress ©) JoVE Example 1 Thu Dee 15 2022 10:02:33 severnr OW % FIO oinece Thu Dee 15 2022 10:02:33 @ avavzen 1 Thu Oct 27 2022.21:12:11 PDAC_060
Slide 25: Image Viewer
Image Viewer User Storage 0.21/10.00 GB i Organoids Analysis JoVE Run1 | a Single Spheroid Gee aS) Monolayer Default Methods Custom Tubes <Back Analyze Default Parameters
Slide 26: JoVE Run
JoVE Run 1 Raw Mask
Slide 27: Tumoroid Screening Lab
Tumoroid Screening Lab Tumoroid Biobank High-throughput Spark Cyto System Confocal imaging Complex microtumor models Orbits integration Proprietary image analysis modules and co-culture screening assays www.orbits-oncology.com [email protected] 27 For research use only. Not for use in d
Slide 28: www.orbits-oncology.com
Maxim Le Compte Prof. dr. Filip Lardon Sofía Peeters Prof. dr. Evelien Smits Felicia Rodrigues Fortes Edgar Cardenas De La Hoz Prof. dr. Hans Prenen Abraham Lin Prof. dr. Marc Peeters Dr. Geert Roeyen Dr. Jeroen Hendriks www.orbits-oncology.com 28